LOGIN  |  REGISTER
Cue Biopharma

Auna Announces Reporting Dates for Third Quarter 2024 Financial Results

October 30, 2024 | Last Trade: US$6.60 0.48 -6.78

LUXEMBOURG / Oct 30, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Third Quarter 2024 financial results.

Earnings Release

Tuesday, November 19, 2024

Time: After Market Close

Conference Call

Wednesday, November 20, 2024

Time: 8:00 a.m. ET

Quiet Period

Monday, November 11 through Tuesday, November 19, 2024

To participate, please dial

+1 888 596 4144 (Toll-Free)

+1 646 968 2525 (International)

Entry Passcode: 3884034

Webcast: click here

About Auna

Auna is a leading healthcare platform in Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of June 30, 2024, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.2 million healthcare plans.

For more information visit www.aunainvestors.com

Stock Quote

Last Trade: US$6.60
Daily Change: -0.48 -6.78
Daily Volume: 32,135
Market Cap: US$198.000M

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB